Venus Medtech Company Keystone Heart has secured CE Mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) device, which minimises the risk of cerebral complications during transcatheter heart procedures.

Cerebrovascular complications are considered the most feared threats in the Transcatheter Aortic Valve Implantation (TAVI) and other transcatheter heart procedures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TriGUARD 3 CEP device deflects embolic debris away from cerebral circulation to reduce the chances of cerebral damage during such procedures.

It is the only CE Marked device created to cover and protect all three major cerebral aortic arch vessels.

Furthermore, the device features Nitinol frame and dome-shaped mesh deflector, delivered transfemorally and devised to ‘self-position’ in the aortic arch.

This design enables the device to adapt to different patient anatomies.

Keystone Heart president and CEO Chris Richardson said: “Taking into consideration the devastating impact of stroke, we are pleased to bring this important technology to patients undergoing any transcatheter heart procedure.

“The introduction of the TriGUARD 3 CEP Device in Europe provides physicians with the only commercially available device that is designed to protect all three cerebral vessels.”

In June 2018, the company initiated a pivotal randomised Phase II clinical trial (REFLECT) of its TriGUARD 3 CEP device, intended to assess the safety and efficacy of the device in around 275 patients. It was recently completed by Keystone Heart.

Currently, the company is finalising data analysis to approach the US Food and Drug Administration (FDA) with the marketing application.